CoStar Catheter System Evaluation

Conor Medsystems2 个研究点分布在 1 个国家目标入组 58 人开始时间: 2007年2月1日最近更新: 2009年10月29日

适应症

试验速览

To evaluate product performance and safety of the Catheter Design for the treatment of a single coronary lesion.

•Patient is ≥18 years of age.
•Eligible for percutaneous coronary intervention (PCI).
•Documented stable or unstable angina pectoris (Canadian Cardiovascular Society Classification [CCS] 1, 2, 3, or 4), documented ischemia, or documented silent ischemia.
•Left ventricular ejection fraction (LVEF) ≥25% documented within the last 6 weeks.
•Acceptable candidate for coronary artery bypass graft surgery (CABG).
•Patient understands the study requirements and the treatment procedures and provides written Informed Consent using a form that has been approved by the local Institutional Review Board or Ethics Committee before any study-specific tests or procedures are performed.
•Willing to comply with all specified follow-up evaluations.
•Inclusion Criteria (Angiographic):
•A single de novo lesion per study subject may be treated with the study device.
•Each target lesion may be composed of multiple lesions but must be completely coverable by one (1) study stent.
•Cumulative target lesion length per vessel is ≤24 mm based on a visual estimate.
•RVD of ≥2.5 mm to ≤3.0 mm based on a visual estimate.
•Target lesion diameter stenosis ≥50% and <100% based on a visual estimate.
•Target vessel has not undergone prior revascularization within the preceding 6 months.
•Target lesion must be a minimum of 10 mm distance from any previously treated segment of the target vessel

•Known sensitivity to cobalt chromium, paclitaxel or polymeric matrices: PLGA.
•Planned treatment with any other PCI device in the target vessel(s).
•Acute MI within 72 hours prior to the index procedure as defined by the presence of a new pathologic Q wave, or creatinine kinase (CK) >2 times the laboratory upper limits of normal and elevated MB.
•The patient is in cardiogenic shock.
•Cerebrovascular Accident (CVA) within the past 6 months.
•Acute or chronic renal dysfunction (creatinine >2.0 mg/dl or >150 µmol/L).
•Contraindication to ASA or to clopidogrel.
•Thrombocytopenia (platelet count <100, 000/mm3).
•Active gastrointestinal (GI) bleeding within the past three months.
•Any prior true anaphylactic reaction to contrast agents.

发起方

Conor Medsystems

申办方类型

Industry

Loading locations...